We would love to hear your thoughts about our site and services, please take our survey here.
Given how low risk mNRA vaccines are, and that they really only give information to the body, I don't think we need to be worried about them impacting the virus negatively (or positively if you're the virus). It is an interesting point to know how the body might respond if has already recognised and actively fighting the virus, although I doubt it would have a negative consequence. I've asked someone who will know, and will revert here when I hear back.
Ultimately though this is an extremely safe vaccine and people do not need to worry (although I don't know the specific answer to this point I am confident it has been explored).
Along with other vaccines it's a very exciting time for immunology.
Scardey, I'm not sure that the vaccine would give the virus a boost if already present. The protein made by the mRNA is more of a 'photo fit' so the body can recognise the live virus. If already recognised I don't know that it would have any impact on the immune response.
However, I would imagine they do need to test for the virus before administering, I can't actually find anything on this though.
I guess there are two strands here. Safety and effectiveness.
With safety - the Moderna vaccine absolutely does not pose any risk to DNA. I think this may have come from a misconception because the vaccine contains a part of the virus genetic material (RNA). However it is absolutely not true this vaccine can have any impact on a human cell. This is novel as a vaccine, BUT multiple studies have been conducted on the effect of mRNA in human cells, in the past, and it has been proved to be safe. Being a new tech is not a reason to fear it.
As to effectiveness, I don't think many people view vaccines as a panacea. They will form a part of the overall response, we will still need to test people regularly, wear masks and even be conscious of social distance for a very long time.
Agent - They absolutely are not guinea pigs. As Rich notes there have been no corners cut in any of the vaccines developed. The reason they have been able to complete all the necessary trials and hurdles so fast is because there is an unprecedented amount of resources being thrown at this, as well as a huge number of willing participants, who have also stuck around for the whole trial (often participants drop away). Aside from the copious amount of data showing these vaccines are safe and effective, it is also completely illogical to think that governments, agencies and pharma companies would be willing to put an unproven product into the market. It wouldn't happen and isn't happening.
Wiggly - this is a common misconception. The effectiveness of the vaccine is in relation to a group not given it. They have been shown to be effective in the over 65 most vulnerable group, in comparison to similar people in the non vaccinated group. Whether or not vulnerable people isolate more is irrelevant when comparing two similar groups with similar behaviours.
I think you might be being a little too down on Avacta, it's true that they have made a number of mistakes recently, most notably not being forthright about delays and being overly positive in RNS language. AS share sale was ill-advised and exposed the company to unnecessary governance questions (which really should not have occurred).
However, the fund raise was very sensible and, I think, the price was correct, as it accounted for some uplift from covid but didn't over extend that risk. Biotech firms are notoriously difficult to grow and a massive cash injection is very welcome, and will see this company through quite a long time without needing to raise new funds.
It sounds like there's been a lot of good tech development in the last 6 months and hopefully that will translate to a saleable product(s). It would be good to have much more clarity around this, but I wouldn't be too disheartened about it. Even without covid products I think the current price will move upwards by this time next year.
I think it's because you now have to have an account to read the chat. I've been reading it on and off for ages but I guess now i actually have an account I decided to join in.
To be clear I'm not down on AVCT and personally think the current price is probably where I would have expected it to be without Covid. But it is frustrating to see that the leadership team seem not to be being especially clear about where things actually are / managing expectations.
I'm also confused. I've held this stock for a little over a year and have mostly seen the covid products as a cash cow for the main business. I've just gone through all the last RNS and it does seem like the timeline has taken a very long time. Maybe I'm missing something?
09/06
The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.
22/07
Avacta… is pleased to announce that it has begun work with the UK government's CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry ("BAMSTM") laboratory assay developed with Adeptrix (Beverly, MA, USA).
The work with the CONDOR programme will commence immediately to evaluate the test performance using real patient samples and will quickly progress to full clinical validation.
07/08
LSTM is currently evaluating the performance of prototype lateral flow tests provided by Cytiva alongside Avacta's ELISA laboratory test using SARS-CoV-2 coronavirus samples, as a precursor to full clinical validation studies.
02/09
Avacta recently announced a manufacturing partnership with BBI Solutions to develop and validate a scaled-up manufacturing process for the rapid coronavirus antigen test. Avacta, Cytiva and BBI are in the process of technology transfer of the prototype and related manufacturing procedures for thetest.
Avacta aims to begin clinical validation of the test as soon as possible using the first pilot batches.
23/11
The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study with COVID-19 patients of known viral load to determine the clinical sensitivity of the test. In parallel BBI Solutions is working to finalise and validate the manufacturing process so that the Group can carry out a full clinical validation on the final product to support the regulatory approval process.
Obviously, as a holder, it would be brilliant to be part of the tender, but a part of me hopes that we aren't: Personally, I think AS share sale does open questions of governance and if we are in the tender after the last RNS I think that would add to AS problems surrounding governance.